Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Antidepressant or Neuroactive steroid or Stimulant

Use the filters below to narrow your results.

generic:
None (2)
brand:
None (43) · Anafranil (1) · Aurorix (1) · Benzedrex (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1) · Zulresso (1) · Zurzuvae (1)
classes: (Click arrow to add another value)
mechanism:
Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Selective norepinephrine reuptake inhibitor (4) · Irreversible non-selective MAO inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2) · Serotonin–norepinephrine reuptake inhibitor (2)
uses:
None (61) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1)
starting dose:
None (61) · 25 mg (1) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)
preparations:
None (61) · 100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)
fda max:
None (61) · 200 mg/d (1) · 50 mg/d × 14 d (1) · Single 60-hour course (1)
routes:
None (60) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (3)
onset:
None (60) · Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Day 3 of dosing in trials; sustained through day 45 (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)
duration:
None (60) · 14-day course; effect persists after discontinuation in trials (1) · Chronic daily dosing (1) · Long (1) · Single infusion course (1)
halflife:
None (60) · ~12 hours (1) · ~16-23 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~9 hours (terminal) (1)
bioavailability:
None (60) · 100% (IV) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Adequate (food-dependent, must take with fatty meal) (1) · ~50% (highly variable) (1)
pregnancy:
None (60) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1)
legal:
None (60) · Rx, Schedule IV (US) (1) · Rx-only (1) · Rx-only in US (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1)

Showing below up to 64 results in range #1 to #64.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"